ArticleAntimicrobial agents and chemotherapy2017
VraR Binding to the Promoter Region of
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Disruption of Functional Membrane Microdomains Enhances Methicillin-ResistantVeterinary sciences · 2026Article
- Staphylococcus aureus sensor histidine kinase VraS mutations linked to antibiotic resistance affect enzymatic catalysis, stability, and substrate interactions.Archives of biochemistry and biophysics · 2026Article
- Loratadine decreases virulence of methicillin-resistantbioRxiv : the preprint server for biology · 2025Article
- Article
- Combatting Antibiotic-ResistantJournal of chemical information and modeling · 2024Article
- AgrA directly binds to the promoter ofAntimicrobial agents and chemotherapy · 2024Article
- Modulation of MRSA virulence gene expression by the wall teichoic acid enzyme TarO.Nature communications · 2023Article
- The first genomic characterization of a stable, hemin-dependent small colony variant strain ofFrontiers in microbiology · 2023Article
- A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus.Journal of advanced research · 2022Article
- Adaptive laboratory evolution and independent component analysis disentangle complex vancomycin adaptation trajectories.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Structural insights into DNA binding domain of vancomycin-resistance-associated response regulator in complex with its promoter DNA from Staphylococcus aureus.Protein science : a publication of the Protein Society · 2022Article
- Article
- Cell wall thickness and the molecular mechanism of heterogeneous vancomycin-intermediate Staphylococcus aureus.Letters in applied microbiology · 2021Article
- Resistome ofACS infectious diseases · 2020Article
- Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-SensitiveFrontiers in microbiology · 2020Article
- VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-ResistantmSphere · 2019Article
- Heterogeneous Vancomycin-IntermediateFrontiers in microbiology · 2019Article
- The Two-Component Signaling System VraSRInfection and immunity · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquisition of vancomycin resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.